ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1866 • 2018 ACR/ARHP Annual Meeting

    Incidence of Inflammatory Bowel Disease Among Patients Treated with Ixekizumab: An Update on Adjudicated Data from an Integrated Database of Patients with Psoriasis and Psoriatic Arthritis

    Mark C. Genovese1, Jean-Frederic Colombel2, Amanda M. Gellett3, Wen Xu3 and Dana Hardin3, 1Department of Medicine, Stanford University, Palo Alto, CA, 2Department of Gastroenterology, The Mount Sinai Hospital, New York, NY, 3Eli Lilly and Company, Indianapolis, IN

    Background/Purpose: Increased incidence of IBD, such as Crohn’s disease (CD) and ulcerative colitis (UC), has been observed in patients (pts) with PsA or plaque psoriasis…
  • Abstract Number: 1867 • 2018 ACR/ARHP Annual Meeting

    Drug Retention and Response Rates of TNFi Treatment in 21,470 Patients with Axial Spondyloarthritis Treated in Clinical Practice– Pooled Data from the Eurospa Research Network Collaboration

    Cecilie Heegaard Brahe1, Lykke Midtbøll Ørnbjerg1, Johan Askling2, Adrian Ciurea3, Eirik K Kristianslund4, Fatos Onen5, Dan Nordström6, Maria José Santos7, Catalin Codreanu8, Ziga Rotar9, Björn Gudbjornsson10, Daniela Di Giuseppe2, Michael J. Nissen11, Tore Kvien4, Merih Birlik5, Nina Trokovic6, Anabela Barcelos7, Ruxandra Ionescu8, Matija Tomšič9, Arni Jon Geirsson10, Anne Gitte Loft1, Herman F Mann12, Tamara Rusman13, Juan J. Gomez-Reino14, Gareth T. Jones15, Florenzo Iannone16, Karel Pavelka12, Irene van der Horst-Bruinsma17, Lise Hyldstrup1, Niels Steen Krogh18, Merete Lund Hetland1 and Mikkel Østergaard1, 1DANBIO, EuroSpA Research Collaboration Network, Coordinating Centre, Copenhagen, Denmark, 2ARTIS, EuroSpA Research Collaboration Network, Stockholm, Sweden, 3SCQM, EuroSpA Research Collaboration Network, Zurich, Switzerland, 4NOR-DMARD, EuroSpA Research Collaboration Network, Oslo, Norway, 5TURKBIO, EuroSpA Research Collaboration Network, Izmir, Turkey, 6ROB-FIN, EuroSpA Research Collaboration Network, Helsinki, Finland, 7Reuma.pt, EuroSpA Research Collaboration Network, Lisbon, Portugal, 8RRBR, EuroSpA Research Collaboration Network, Bucharest, Romania, 9biorx.si, EuroSpA Research Collaboration Network, Ljubljana, Slovenia, 10ICEBIO, EuroSpA Research Collaboration Network, Reykjavik, Iceland, 11SCQM, EuroSpA Research Collaboration Network, Geneva, Switzerland, 12ATTRA, EuroSpA Research Collaboration Network, Prague, Czech Republic, 13ARC, EuroSpA Research Collaboration Network, Haarlem, Netherlands, 14BIOBADASER, EuroSpA Research Collaboration Network, Santiago, Spain, 15BSRBR-AS, EuroSpA Research Collaboration Network, Aberdeen, United Kingdom, 16GISEA, EuroSpA Research Collaboration Network, Bari, Italy, 17ARC, EuroSpA Research Collaboration Network, Harleem, Netherlands, 18Zitelab, EuroSpA Research Collaboration Network, Copenhagen, Denmark

    Drug retention and response rates of TNFi treatment in 21,470 patients with axial spondyloarthritis treated in clinical practice– pooled data from the EuroSpA Research Network…
  • Abstract Number: 1868 • 2018 ACR/ARHP Annual Meeting

    Efficacy and Safety Outcomes in Patients with Non-Radiographic Axial Spondyloarthritis Treated with Certolizumab Pegol: Results from the First 52-Week Randomized Placebo-Controlled Study (NCT02552212)

    Atul A. Deodhar1, Lianne S. Gensler2, Jonathan Kay3, Walter P. Maksymowych4, Nigil Haroon5, Robert B.M. Landewé6, Martin Rudwaleit7, Stephen Hall8, Lars Bauer9, Bengt Hoepken9, Natasha de Peyrecave10, Brian Kilgallen11 and Désirée van der Heijde12, 1Oregon Health and Science University, Portland, OR, 2University of California San Francisco, San Francisco, CA, 3Division of Rheumatology, University of Massachusetts Medical School and UMass Memorial Medical Center, Worcester, MA, 4Department of Medicine, University of Alberta, Edmonton, AB, Canada, 5University Health Network, University of Toronto, Toronto, ON, Canada, 6Amsterdam Rheumatology & Clinical Immunology Center and Zuyderland Medical Center, Amsterdam; Heerlen, Netherlands, 7Department of Internal Medicine and Rheumatology, Klinikum Bielefeld, Bielefeld, Germany, 8Cabrini Medical Centre, Cabrini Private Hospital, Malvern, Australia, 9UCB Pharma, Monheim, Germany, 10UCB Pharma, Brussels, Belgium, 11UCB Pharma, Raleigh, NC, 12Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: In the USA, certolizumab pegol (CZP) is approved for treatment of adults with active ankylosing spondylitis (AS) and not for non-radiographic axial spondyloarthritis (nr-axSpA).…
  • Abstract Number: 1869 • 2018 ACR/ARHP Annual Meeting

    Sustained Improvements in Signs and Symptoms of Active Ankylosing Spondylitis and Reassuring Safety with Secukinumab 300mg: 3-Year Results from a Phase 3 Study

    Alan J. Kivitz1, Karel Pavelka2, Eva Dokoupilova3, Ricardo Blanco4, Marco Maradiaga5, Hasan Tahir6, Yi Wang7, Brian Porter8, Anna Stefanska9, Susanne Rohrer10 and Hanno Richards10, 1Altoona Center for Clinical Research, Duncansville, PA, 21st Faculty of Medicine, Charles University, Institute of Rheumatology and Department of Rheumatology, Prague, Czech Republic, 3University of Veterinary and Pharmaceutical sciences, Faculty of Pharmacy, Department of Pharmaceutics, MEDICAL PLUS s.r.o.,, Uherske Hradiste, Czech Republic, 4Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 5Centro de Investigación de Tratamientos Innovadores de Sinaloa, Culiacán, Mexico, 6Rheumatology, Barts Health NHS Trust, London, United Kingdom, 7Novartis Pharmaceuticals Corporation, East Hanover, NJ, 8Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, 9Novartis Ireland Limited, Dublin, Ireland, 10Novartis Pharma AG, Basel, Switzerland

    Background/Purpose: Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis (AS) over 2 years in the MEASURE 3 study, which…
  • Abstract Number: 1870 • 2018 ACR/ARHP Annual Meeting

    Phase 2 Trial of Induction Therapy with Anti-CD20 (Rituximab) Followed By Maintenance Therapy with Anti-BAFF (Belimumab) in Patients with Active Lupus Nephritis

    Maria Dall'Era1, Cynthia Aranow2, Margaret Byron3, Linna Ding4, Dawn Smilek5, Betty Diamond6 and David Wofsy7, 1University of California, San Francisco, San Francisco, CA, 2The Feinstein Institute for Medical Research, Manhasset, NY, 3Rho Federal Systems, Inc., Chapel Hill, NC, 4National Institute of Allergy and Infectious Diseases, Bethesda, MD, 5Immune Tolerance Network, San Francisco, CA, 6Autoimmune Musculoskeletal and Hematopoietic Diseases, The Feinstein Institute for Medical Research, Manhasset, NY, 7Rheumatology, University of California, San Francisco, San Francisco, CA

    Background/Purpose: Two randomized, controlled trials of rituximab in patients with lupus and lupus nephritis (LN) did not meet their primary endpoints. A potential explanation is…
  • Abstract Number: 1871 • 2018 ACR/ARHP Annual Meeting

    A High Cardiovascular Biomarker Panel Risk Score Is Associated with Increased 10-Year Risk of Cardiovascular Events and Death in SLE

    Maureen A. McMahon1, Jennifer M. Grossman2, Lori Sahakian3, Christina Charles-Schoeman4, John Fitzgerald1, Mihaela Taylor4, Alan Gorn1, Eloise Olmos1, Daniel J. Wallace5, Bevra H Hahn1,4 and Brian Skaggs4, 1Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, 2Div of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, 3UCLA David Geffen School of Medicine, Los Angeles, CA, 4Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, 5Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA

    Background/Purpose: There is a well-documented increase in atherosclerosis (ATH) in SLE that is not fully explained by traditional risk factors. Several non-Framingham biomarkers, including pro-inflammatory…
  • Abstract Number: 1872 • 2018 ACR/ARHP Annual Meeting

    Safety and Efficacy of Allogeneic Umbilical Cord-Derived Mesenchymal Stem Cells in Patients with Systemic Lupus Erythematosus: Results of an Open-Label Phase I Study

    Diane L. Kamen1, Paul J. Nietert2, Hongjun Wang3, Tara Duke3, Colleen Cloud3, Angela Robinson3 and Gary S. Gilkeson4, 1Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, 2Public Health Sciences, Medical University of South Carolina, Charleston, SC, 3Medical University of South Carolina, Charleston, SC, 4Department of Medicine, Medical University of South Carolina, Charleston, SC

    Background/Purpose: Mesenchymal stem cells (MSCs) are known to possess significant immunosuppressive and tissue protective properties, and their use in refractory systemic lupus erythematosus (SLE) is…
  • Abstract Number: 1873 • 2018 ACR/ARHP Annual Meeting

    Age- and Cause-Specific Standardized Mortality Ratio of Systemic Lupus Erythematosus Patients in Ontario, Canada over 43 Years (1971-2013)

    Konstantinos Tselios, Dafna D Gladman, Barry Sheane, Jiandong Su and Murray Urowitz, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: The major causes of early death in systemic lupus erythematosus (SLE) include active disease and infections, while cardiovascular complications and malignancies dominate the late…
  • Abstract Number: 1874 • 2018 ACR/ARHP Annual Meeting

    Remission and Low Disease Activity State Are Protective of Intermediate and Long-Term Outcomes in SLE Patients. Data from a Multi-Ethnic, Multi-Center US Cohort

    Guillermo J. Pons-Estel1,2, Graciela S. Alarcón3, Manuel Ugarte-Gil4,5, Luis M. Vilá6, John D. Reveille7 and Gerald McGwin3, 1Rheumatology, Hospital Provincial de Rosario, Rosario, Argentina, 2Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario. Argentina, Rosario, Argentina, 3University of Alabama at Birmingham, Birmingham, AL, 4Rheumatology, Universidad Científica del Sur, Lima, Peru, 5Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, 6Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, 7McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX

    Background/Purpose: Over the last few years the importance of treating patients with SLE towards achieving either Remission or LDAS (Treat-to-Target approach) has become evident. We…
  • Abstract Number: 1875 • 2018 ACR/ARHP Annual Meeting

    Influence of Setting an Upper Limit of the Modified Rodnan Skin Score As an Inclusion Criterion in Systemic Sclerosis Clinical Trials on the Ratio of Skin Fibrosis Progression Vs. Improvement – an Analysis of the Genisos Cohort

    Carina Mihai1,2, Rucsandra Dobrota1,2, Shervin Assassi3, Maureen D. Mayes3 and Oliver Distler1, 1Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 2Internal Medicine and Rheumatology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, 3Rheumatology, University of Texas Health Science Center at Houston, Houston, TX

    Background/Purpose: Recent studies on large cohorts of patients with systemic sclerosis (SSc) have shown that lowering the upper threshold of the modified Rodnan skin score…
  • Abstract Number: 1876 • 2018 ACR/ARHP Annual Meeting

    Machine Learning Classification of Peripheral Blood Gene Expression Identifies a Subset of Patients with Systemic Sclerosis Most Likely to Show Clinical Improvement in Response to Hematopoietic Stem Cell Transplant

    Jennifer Franks1, Viktor Martyanov2, Tammara A. Wood2, Leslie Crofford3, Lynette Keyes-Elstein4, Daniel E. Furst5, Ellen Goldmuntz6, Maureen D. Mayes7, Peter McSweeney8, Richard Nash8, Keith Sullivan9 and Michael L. Whitfield10, 1Geisel School of Medicine at Dartmouth, Hanover, NH, 2Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, 3Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, 4Rho, Inc, Chapel Hill, NC, 5University of California Los Angeles, Los Angeles, CA, 6NIAID, NIH, Bethesda, MD, 7Rheumatology, University of Texas McGovern Medical School, Houston, TX, 8Colorado Blood Cancer Institute, Denver, CO, 9Duke University Medical Center, Durham, NC, 10Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hanover, NH

    Background/Purpose: The SCOT (Scleroderma: Cyclophosphamide or Transplantation) trial (Sullivan K. et al, 2018) demonstrated the clinical benefit of hematopoietic stem cell transplant (HSCT) compared to…
  • Abstract Number: 1877 • 2018 ACR/ARHP Annual Meeting

    Specific Pneumoproteins Predict Progression of Interstitial Lung Disease in Systemic Sclerosis Patients Undergoing Treatment with Immunosuppression

    Elizabeth R. Volkmann1, Donald P. Tashkin1, Masataka Kuwana2, Ning Li3, Julio Charles4, Faye N. Hant5, Galina S. Bogatkevich6, Tanjina Akter6, Michael Roth7, Hyun J. Grace Kim8, Jonathan Goldin9, Dinesh Khanna10, Philip J. Clements11, Daniel E. Furst7, Robert Elashoff12, Rick Silver13 and Shervin Assassi14, 1University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 2Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 3Biomathematics, University of California, Los Angeles, Los Angeles, CA, 4University of Texas Health Science Center at Houston, Houston, TX, 5Rheumatology, Medical University of South Carolina, Charleston, SC, 6Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, 7Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 8Department of Radiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, 9Department of Radiological Sciences at UCLA, University of California, Los Angeles, David Geffen School of Medicine, Santa Monica, CA, 10Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, 11Medicine, University of California, Los Angeles, Los Angeles, CA, 12University of California, Los Angeles, Los Angeles, CA, 13Rheumatology, Medical University of SC, Charleston, SC, 14University of Texas McGovern Medical School, Houston, TX

    Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in systemic sclerosis (SSc). While some SSc-ILD patients are stable or improve with immunosuppressive…
  • Abstract Number: 1878 • 2018 ACR/ARHP Annual Meeting

    Immunosuppression in Diffuse Systemic Sclerosis Improves Outcomes Using a Novel Composite Response Index

    Boyang Zheng1, Mianbo Wang2 and Murray Baron3, 1Rheumatology, McGill University Health Center (MUHC), Montreal, QC, Canada, 2Lady Davis Institute for Medical Research, Montreal, QC, Canada, 3Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada

    Background/Purpose: Diffuse systemic sclerosis (dcSSc) is a devastating multi-organ disease where the mainstay of treatment is immunosuppression. Data on these therapies are mostly based on…
  • Abstract Number: 1879 • 2018 ACR/ARHP Annual Meeting

    The Effects of Riociguat on Raynaud’s Phenomenon and Digital Ulcers in Patients with Diffuse Systemic Sclerosis: Results from the Phase IIb RISE-SSc Study

    Dinesh Khanna1, Yannick Allanore2, Christopher P. Denton3, Masataka Kuwana4, Marco Matucci-Cerinic5, Janet E. Pope6, Janethe Pena7, Kaisa Laapas8, Zhen Yao9 and Oliver Distler10, 1Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, 2Rheumatology A Department, Cochin Hospital, Paris Descartes University, Sorbonne Paris Cité, Paris, France, 3UCL Division of Medicine, Royal Free Campus, London, United Kingdom, 4Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 5Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, 6Department of Medicine, University of Western Ontario, London, ON, Canada, 7Clinical Development, Bayer US LLC, Whippany, NJ, 8StatFinn Oy, Espoo, Finland, 9Bayer AG, Berlin, Germany, 10Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland

    Background/Purpose: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of pulmonary arterial hypertension associated with connective tissue disease. It was anticipated that…
  • Abstract Number: 1880 • 2018 ACR/ARHP Annual Meeting

    Cardiovascular (CV) Risk Factors and Atherosclerotic CV Events Among Incident Cases of Systemic Sclerosis: Results from a Population Based Cohort (1980-2016)

    Avneek Singh Sandhu1, Reto Kurmann2, Cynthia S. Crowson3, Rekha Mankad2, Eric L. Matteson4, Thomas Osborn1, Kenneth J. Warrington5 and Ashima Makol1, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Cardiovascular Diseases, Mayo Clinic College of Medicine and Science, Rochester, MN, 3Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, 4Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, 5Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN

    Background/Purpose: Cardiac involvement, due to impairment of coronary microcirculation and myocardial fibrosis, affects prognosis in individuals with SSc, and represents one of the leading causes…
  • « Previous Page
  • 1
  • …
  • 1127
  • 1128
  • 1129
  • 1130
  • 1131
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology